Carol Gallagher, Pharm.D., joined NEA in October, 2014. She is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with more than 25 years of experience in commercial, drug development and business development roles in small and large Pharma. Prior to joining NEA she was a Venture Partner with Frazier Healthcare. From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. Gilead Sciences acquired Calistoga Pharmaceuticals in April 2011 for a total consideration of $600 million. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously. Carol currently serves as Chairman of Millendo and a Director at Cleave Biosciences, Atara Bio, and AnaptysBio.